Home » Stocks » Odonate Therapeutics

Odonate Therapeutics, Inc. (ODT)

Stock Price: $38.70 USD 0.11 (0.29%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.24B
Revenue (ttm) n/a
Net Income (ttm) -113.34M
Shares Out 32.11M
EPS (ttm) -3.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $38.70
Previous Close $38.59
Change ($) 0.11
Change (%) 0.29%
Day's Open 38.74
Day's Range 38.16 - 39.43
Day's Volume 43,275
52-Week Range 18.07 - 46.50

More Stats

Market Cap 1.24B
Enterprise Value 1.09B
Earnings Date (est) Aug 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.11M
Float 12.54M
EPS (basic) -3.92
EPS (diluted) -3.89
FCF / Share -3.19
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 764,257
Short Ratio 10.52
Short % of Float 4.91%
Beta 1.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.18
Revenue n/a
Operating Income -116.53M
Net Income -113.34M
Free Cash Flow -97.52M
Net Cash 151.86M
Net Cash / Share 4.73
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -51.57%
ROE -97.00%
ROIC 807.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

(11.11% upside)
Current: 38.70
Target: 43.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-115-90.76-32.74-3.09-0.16
Net Income-112-88.96-32.74-3.09-0.16
Shares Outstanding27.6324.4614.175.760.92
Earnings Per Share-4.05-3.64-2.31-0.54-0.17
Operating Cash Flow-96.64-67.09-25.86-1.73-0.17
Capital Expenditures-0.17-1.91-0.08--
Free Cash Flow-96.80-69.00-25.94-1.73-0.17
Cash & Equivalents1811391982.600.14
Total Debt2.06----
Net Cash / Debt1791391982.600.14
Book Value1621241962.280.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Odonate Therapeutics, Inc.
Country United States
Employees 134
CEO Kevin C. Tang

Stock Information

Ticker Symbol ODT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ODT
IPO Date December 7, 2017


Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.